FILTER
FILTERED INTERVIEW RESULTS
Dr. Jagadeesh Babu Rangisetty
FOUNDER & CEO, BIOPHORE
Biophore explains how it is expanding productions of different APIs to ensure both quality and supply chain security.
James Gale
CEO, SIGNET HEALTHCARE PARTNERS
Signet Healthcare Partners speaks to GBR about how it is evolving its’ investment portfolio in life sciences.
Emer Leahy
PRESIDENT AND CEO, PSYCHOGENICS
PsychoGenics explains how CNS is attracting unprecedented attention and how its AI-driven phenotypic discovery platforms can help to deliver cures.
Keith Crandell
CO-FOUNDER & MANAGING DIRECTOR, ARCH VENTURE PARTNERS
ARCH Venture Partners explains the secrets to successful innovation in todays’ life sciences.
Daniel J. O’Connor
PRESIDENT & CEO, ONCOSEC MEDICAL INCORPORATED
OnoSec Medical explains how treating cancers with a plasmid-based approach can avoid side effects and work on immunologically cold tumors.
Jorge Nogueira
CEO, DIPHARMA FRANCIS
Dipharma speaks to GBR of how it is adapting to market trends and expanding its geography.
Peter Meath
CO-HEAD OF HEALTHCARE AND LIFE SCIENCES, MIDDLE MARKET, J.P. MORGAN COMMERCIAL BANKING
"While the underlying business model for life sciences companies hasn’t changed as a result of our current environment, we’re seeing that increased capital has been made available to those seeking funding. This makes it an incredibly promising time for the sector."
Timothy J. Miller
PRESIDENT & CEO, FORGE BIOLOGICS
"What we are seeing is a reflection of the power of genetic medicine, where the technology has demonstrated clinical promise, as well as safety. Now, in many aspects, it is up to the manufacturing to catch up as that demand for gene therapy manufacturers far exceeds the capacity."
Lesley Millar-Nicholson
DIRECTOR, MIT TECHNOLOGY LICENSING OFFICE
"MIT spins out over 32 startup companies per year approximately, and we have about 358 companies that are still alive, so the ecosystem is functioning well."
Robert E. Landry
EXECUTIVE VICE PRESIDENT, FINANCE AND CHIEF FINANCIAL OFFICER, REGENERON
Regeneron explains how its capabilities for target discovery and validation are enabled by a series of Regeneron-invented technologies that accelerate, improve and disrupt the traditional drug discovery and development process.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
Peru Mining 2025 Pre-Release II
Featuring insights from nearly 50 mining executives, the second pre-release edition of GBR's Peru Mining 2025 sheds light on the industry's current state while highlighting the country's window of opportunity with the energy transition and copper's critical role.
Featuring insights from nearly 50 mining executives, the second pre-release edition of GBR's Peru Mining 2025 sheds light on the industry's current state while highlighting the country's window of opportunity with the energy transition and copper's critical role.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
